Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.48 |
| ▸ | MLNR | O43193 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | INSR | P06213 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | CCKAR | P32238 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30011721 | 1.00 | EGFR (0.48) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL30011521 | 0.92 | EGFR (0.47) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL18386962 | 0.92 | EGFR (0.49) | EGFR | |
| SCHEMBL20162196 | 0.92 | EGFR (0.47) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL18386768 | 0.92 | EGFR (0.50) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL30011528 | 0.88 | EGFR (0.46) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL20162206 | 0.88 | EGFR (0.46) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL20162215 | 0.86 | KDR (0.38) | EGFRKDR | |
| SCHEMBL30011737 | 0.86 | KDR (0.38) | EGFRKDR | |
| SCHEMBL18386891 | 0.85 | EGFR (0.46) | EGFRMLNRKDM1AABCB11ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329277-B2 | N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(3-methyl-2-OXO-2,3-dihydro-1h-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide hydrochloride as an inhibitor of epidermal growth factor receptor activity | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-06-25 | — | — | US | disclosed |
| US-10329277-B2 | N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(3-methyl-2-OXO-2,3-dihydro-1h-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide hydrochloride as an inhibitor of epidermal growth factor receptor activity | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-06-25 | — | — | US | disclosed |
| US-20180208581-A1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| US-20180208581-A1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| US-20180208581-A1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| EP-3323817-A1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208581-A1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | EGFR, ERBB2, ERBB3 | EGFR 1/4885MLNR 1842/4885KDM1A 4557/4885 |
| US-10329277-B2 | N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(3-methyl-2-OXO-2,3-dihydro-1h-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide hydrochloride as an inhibitor of epidermal growth factor receptor activity | EGFR, ERBB2, ERBB3 | EGFR 1/4885MLNR 292/4885KDM1A 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.